Verisante Technology Inc., (VRS.V, VRSEF, FSE:3VT) should receive Health Canada approval for the Verisante Aura for the detection of Skin Cancer anytime now. The company expects to receive the CE Mark for European regulatory approval, and Australian regulatory approval by the end of the year. This will enable marketing to begin in Canada, Australia and in Europe in 2012. The market anxiously awaits this exciting news and major milestone that should have a positive impact on volume and price. Verisante has excellent media coverage and as a result has developed a large following across North America, Europe and Australia.

Click here to view blog post.